A scientific collaboration led by researchers from the Institut de Biotecnologia i de Biomedicina (IBB), Autonomous University of Barcelona (UAB), has identified a molecule that stops and reverses the neurodegeneration that causes the Parkison.
A finding that has come after analysis of more than 14,000 molecules and found one, called SynuClean-D, which prevents to start the process that results in triggering the neurodegenerative disease, as reported by UAB on Tuesday in a press release.
The work has been experienced with the worm Caenorhabdiis elegans -the most commonly used for the study of neurodegenerative diseases – in animal models, through the food, and the results have shown that it reduces “significantly” the aggregation of alpha-synuclein, the protein that most accumulates in the neurons that generate dopamine, which is the main feature of this pathology.
In addition, the study has served to confirm that administration of this inhibitor identified has improved the mobility of the animal and protects against neuronal degeneration.
Research coordinator at UAB, Salvador Ventura, has suggested that “may have therapeutic applications to treat neurodegenerative diseases such as Parkinson’s disease in the future.”
In the research have also participated, among others, researchers in the Department of Chemistry of the UAB, the Institute of Neurosciences of the UAB, with the collaboration of researchers from the Institute for Research in Biomedicine (IRB Barcelona), University of Barcelona (UB), the University of Vic – Central University of Catalonia, University of Zaragoza, the University Medical Center of Göttingen (Germany), the University of the Sorbonne (France), the Max Planck Institute for Experimental Medicine (Germany) and the University of Newcastle (Uk).